Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Seligmann, JF, Hatch, AJ, Richman, SD, Elliott, F, Jacobs, B, Brown, S, Hurwitz, H, Barrett, JH, Quirke, P, Nixon, AB, and Seymour, MT. "Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer." JAMA oncology (October 26, 2017).

PMID
29075780
Full Text

Ronald, J, Nixon, AB, Marin, D, Gupta, RT, Janas, G, Chen, W, Suhocki, PV, Pabon-Ramos, W, Sopko, DR, Starr, MD, Brady, JC, Hurwitz, HI, and Kim, CY. "Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma." Radiology 285, no. 1 (October 2017): 311-318.

PMID
28787261
Full Text

Thompson, EM, Keir, ST, Venkatraman, T, Lascola, C, Yeom, KW, Nixon, AB, Liu, Y, Picard, D, Remke, M, Bigner, DD, Ramaswamy, V, and Taylor, MD. "The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival." Neuro-oncology 19, no. 9 (September 2017): 1217-1227.

PMID
28379574
Full Text

Zhang, T, Zhu, J, George, DJ, and Nixon, AB. "Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies." Urologic oncology 34, no. 11 (November 2016): 510-518. (Review)

PMID
27498927
Full Text

Hesler, RA, Huang, JJ, Starr, MD, Treboschi, VM, Bernanke, AG, Nixon, AB, McCall, SJ, White, RR, and Blobe, GC. "TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3." Carcinogenesis 37, no. 11 (November 2016): 1041-1051.

PMID
27604902
Full Text

Hatch, AJ, Sibley, AB, Starr, MD, Brady, JC, Jiang, C, Jia, J, Bowers, DL, Pang, H, Owzar, K, Niedzwiecki, D, Innocenti, F, Venook, AP, Hurwitz, HI, Nixon, AB, and Alliance for Clinical Trials in Oncology, . "Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)." Cancer medicine 5, no. 9 (September 2016): 2249-2260.

PMID
27465221
Full Text

Keefe, SM, Hoffman-Censits, J, Cohen, RB, Mamtani, R, Heitjan, D, Eliasof, S, Nixon, A, Turnbull, B, Garmey, EG, Gunnarsson, O, Waliki, M, Ciconte, J, Jayaraman, L, Senderowicz, A, Tellez, AB, Hennessy, M, Piscitelli, A, Vaughn, D, Smith, A, and Haas, NB. "Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial." Annals of oncology : official journal of the European Society for Medical Oncology 27, no. 8 (August 2016): 1579-1585.

PMID
27457310
Full Text

Innocenti, F, Jiang, C, Sibley, A, Etheridge, A, Furukawa, Y, Kubo, M, Kindler, HL, Venook, AP, Hurwitz, HI, Nixon, AB, and Owzar, K. "Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients." July 15, 2016.

Full Text

Nixon, AB, Sibley, A, Hatch, AJ, Liu, Y, Jiang, C, Mulkey, F, Starr, MD, Brady, JC, Niedzwiecki, D, Innocenti, F, Venook, AP, Hochster, HS, Lenz, H-J, O'Neil, BH, Owzar, K, and Hurwitz, H. "Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance)." May 20, 2016.

Full Text

Secord, AA, Tritchler, D, Liu, Y, Starr, MD, Brady, JC, Lankes, HA, Hurwitz, H, Mannel, RS, Tewari, KS, O'Malley, DM, Gray, HJ, Bakkum-Gamez, JN, Fujiwara, K, Boente, M, Deng, W, Burger, RA, Birrer, MJ, and Nixon, AB. "Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatinpaclitaxel (CP) +/- bevacizumab (BEV). Results from GOG-0218." May 20, 2016.

Scholars@Duke

Pages